Replies to post #796343 on NorthWest Biotherapeutics Inc (NWBO)

[seekinganswers]

You can't just make things up!!! Any approval of DCVax (highly doubtful) would be WITH SOC. It's not up to the patient to decide what they want. DCVax was never tested as a stand alone treatment. I don't know where or from whom you get these wild ideas, but you should certainly change your sources.
"The placebo patients in the phase 3 trial for DCVax-L (NCT00045968) received standard of care (SOC) therapy, which consisted of surgery, radiotherapy, and temozolomide chemotherapy following the Stupp protocol for newly diagnosed glioblastoma.
This design ensured both arms got equivalent SOC, allowing assessment of the vaccine's added benefit"
Good luck.

[sentiment_stocks]

Why do you think that patients in the placebo-arm who relapsed in the trial and then received DCVax-L much later than those in the active-arm group, did better?

Doc, I think we should also consider that these rGBM patients may have also “lived longer” because their returning tumors may have come back with a mesenchymal signature… which TMZ is known to induce in returning gliomas. And while mesenchymal GBM is pretty much the worst of the GBM subtypes (which may be why so many rGBM patients are so short-lived), DCVax-L works best on this subtype. A mesenchymal tumor is more of a “hot” tumor, so they can thereby better attract an immune response, should the TCells actually show up (which DCVax has proven it can effect).